Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients
Alex C Spyropoulos, Walter Ageno, Gregory W Albers, C Gregory Elliott, Jonathan L Halperin, William R Hiatt, Gregory A Maynard, P Gabriel Steg, Jeffrey I Weitz, Wentao Lu, Theodore E Spiro, Elliot S Barnathan, Gary E Raskob, Alex C Spyropoulos, Walter Ageno, Gregory W Albers, C Gregory Elliott, Jonathan L Halperin, William R Hiatt, Gregory A Maynard, P Gabriel Steg, Jeffrey I Weitz, Wentao Lu, Theodore E Spiro, Elliot S Barnathan, Gary E Raskob
Abstract
Background: Hospitalized acutely ill medical patients are at risk for fatal and major thromboembolic events. Whether use of extended-duration primary thromboprophylaxis can prevent such events is unknown.
Objectives: The purpose of this study was to evaluate whether extended-duration rivaroxaban reduces the risk of venous and arterial fatal and major thromboembolic events without significantly increasing major bleeding in acutely ill medical patients after discharge.
Methods: MARINER (A Study of Rivaroxaban [JNJ-39039039] on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients) studied acutely ill medical patients with additional risk factors for venous thromboembolism (VTE). Medically ill patients with a baseline creatinine clearance ≥50 ml/min were randomized in a double-blind fashion to rivaroxaban 10 mg or placebo daily at hospital discharge for 45 days. Exploratory efficacy analyses were performed with the intent-to-treat population including all data through day 45. Time-to-event curves were calculated using the Kaplan-Meier method. A blinded independent committee adjudicated all clinical events.
Results: In total, 4,909 patients were assigned to rivaroxaban and 4,913 patients to placebo. The mean age was 67.8 years, 55.5% were men, mean baseline creatinine clearance was 87.8 ml/min, and mean duration of hospitalization was 6.7 days. The pre-specified composite efficacy endpoint (symptomatic VTE, myocardial infarction, nonhemorrhagic stroke, and cardiovascular death) occurred in 1.28% and 1.77% of patients in the rivaroxaban and placebo groups, respectively (hazard ratio: 0.72; 95% confidence interval: 0.52 to 1.00; p = 0.049), whereas major bleeding occurred in 0.27% and 0.18% of patients in the rivaroxaban and placebo groups, respectively (hazard ratio: 1.44; 95% confidence interval: 0.62 to 3.37; p = 0.398).
Conclusions: Extended-duration rivaroxaban in hospitalized medically ill patients resulted in a 28% reduction in fatal and major thromboembolic events without a significant increase in major bleeding. (A Study of Rivaroxaban [JNJ-39039039] on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients [MARINER]; NCT02111564).
Keywords: hospitalized; major bleeding; medically ill; rivaroxaban; thromboembolic events.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Figures
References
- Piazza G., Fanikos J., Zayaruzny M., Goldhaber S.Z. Venous thromboembolic events in hospitalised medical patients. Thromb Haemost. 2009;102:505–510.
- The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. Office of the Surgeon General; Rockville, MD: 2008. Office of the Surgeon General, National Heart, Lung, and Blood Institute. Publications and reports of the Surgeon General.
- Amin A.N., Varker H., Princic N., Lin J., Thompson S., Johnston S. Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients. J Hosp Med. 2012;7:231–238.
- Piazza G., Goldhaber S.Z. Venous thromboembolism and atherothrombosis: an integrated approach. Circulation. 2010 May 18;121:2146–2150.
- Prandoni P., Bilora F., Marchiori A. An association between atherosclerosis and venous thrombosis. N Engl J Med. 2003;348:1435–1441.
- Gibson C.M., Chi G., Halaby R., for the APEX Investigators Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically ill patients: an APEX trial substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended duration Betrixaban) Circulation. 2017;135:648–655.
- Gibson C.M., Korjian S., Chi G., for the APEX Investigators Comparison of fatal or irreversible events with extended-duration betrixaban versus standard dose enoxaparin in acutely ill medical patients: an APEX trial substudy. J Am Heart Assoc. 2017;6
- Spyropoulos A.C., Ageno W., Albers G.W. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med. 2018;379:1118–1127.
- Weitz J.I., Raskob G.E., Spyropoulos A.C. Thromboprophylaxis with rivaroxaban in acutely ill medical patients with renal impairment: insights from the MAGELLAN and MARINER trials. Thromb Haemost. 2020;120:515–524.
- Raskob G.E., Spyropoulos A.C., Zrubek J. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Thromb Haemost. 2016;115:1240–1248.
- Squizzato A., Lussana F., Ageno W., Cattaneo M. Effect of thromboprophylaxis with anticoagulant drugs on the incidence of arterial thrombotic events in medical inpatients: a systematic review. Intern Emerg Med. 2016;11:467–476.
- Cohen A.T., Harrington R.A., Goldhaber S.Z., for the APEX Investigators Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med. 2016;375:534–544.
- Raskob G.E., Spyropoulos A.C., Cohen A.T. Rivaroxaban for extended thromboprophylaxis after hospitalization for medical illness: pooled analysis of mortality and major thromboembolic events in 16,496 patients from the MAGELLAN and MARINER trials. Circulation. 2019;140:A12863.
- Ageno W., Becattini C., Brighton T., Selby R., Kamphuisen P.W. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation. 2008;117:93–102.
- Tomkowski W.Z., Davidson B.L. Thromboprophylaxis by rivaroxaban, aspirin, both, or placebo after hospitalization for medical illness. Thromb Res. 2019;180:62–63.
- Eikelboom J.W., Connolly S.J., Bosch J., for the COMPASS Investigators Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319–1330.
- Zhang L., Yan X., Nandy P. Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome. Ther Adv Cardiovasc Dis. 2019;13:1–15.
- Willmann S., Zhang L., Frede M. Integrated population pharmacokinetic analysis of rivaroxaban across multiple patient populations. CPT Pharmacometrics Syst Pharmacol. 2018;7:309–320.
- Spyropoulos A.C., Lipardi C., Xu J. Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN Study. Clin Appl Thromb Hemost. 2019;25
Source: PubMed